Non-Cystic Fibrosis Bronchiectasis
Research activity is centred on non-cystic fibrosis bronchiectasis, with attention to patients carrying Pseudomonas aeruginosa and other potentially pathogenic micro-organisms in the airways. The clinical focus reflects interest in persistent respiratory infection and chronic airway disease.
- Chronic suppurative lung disease
- Airway colonisation
- Respiratory infection
Thirty Respiratory Limited is engaged in the therapeutic area of bronchiectasis management, with emphasis on infection-related respiratory morbidity.
Antimicrobial Respiratory Microbiology
The sponsor’s research landscape includes respiratory microbiology linked to high-burden airway pathogens, particularly Pseudomonas aeruginosa and other potentially pathogenic micro-organisms. This area aligns with clinical interest in pathogen persistence within damaged airways.
- Bacterial airway burden
- Respiratory pathogen control
- Microbial persistence
The funded trial activity concentrates on infection-associated respiratory disease rather than broader pulmonary conditions.
Nitric Oxide-Based Inhaled Therapy
Clinical interest also extends to nebulised nitric oxide formulations for inhaled treatment in chronic respiratory infection settings. The sponsor is exploring a respiratory therapeutic approach intended for diseased airways affected by persistent microbial presence.
- Inhaled respiratory therapy
- Nebulised formulations
- Airway-directed treatment
This area connects pharmaceutical development with lung-targeted intervention in patients with bronchiectasis.
Respiratory Safety and Tolerability
The funded research includes evaluation of safety and tolerability in adults with chronic airway infection, supporting clinical interest in treatment acceptability within respiratory medicine. The emphasis is on patients with confirmed high-burden airway organisms.
- Respiratory treatment safety
- Tolerability assessment
- Chronic airway disease
Thirty Respiratory Limited is active in a narrowly defined therapeutic space focused on infection-driven airway disease.
